SLC5A2 and acute kidney injury: However, when taken together, data from recent CV and kidney outcome trials with SGLT2 inhibitors indicate that the risk of AKI is certainly not increased and may even be reduced by this therapy (RR 0.75; 95% CI 0.66–0.85, P < 0.0001) (57).